Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details) - USD ($) $ in Millions			3 Months Ended			6 Months Ended		12 Months Ended
	Jul. 01, 2022	Jun. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Revenues			$ 2,857.2		$ 5,138.5	$ 5,822.3	$ 7,667.2
Sanofi Collaboration Agreement, Antibody
Disaggregation of Revenue [Line Items]
Percentage share of profits to reimburse collaborating party								10.00%
Percentage of share of profits used to reimburse collaborating party for trial costs	20.00%	10.00%
Revenue, remaining performance obligation, variable consideration amount		$ 100.0	100.0			100.0
Sanofi Collaboration Agreement, Antibody | Sales Milestone Three
Disaggregation of Revenue [Line Items]
Revenues				$ 50.0
Levels of twelve-month sales at which sales milestone payments would be received				$ 2,000.0
Period for achieving sales target for milestone payment, rolling basis				12 months
Sanofi Collaboration Agreement, Antibody | Sales Milestone Four
Disaggregation of Revenue [Line Items]
Levels of twelve-month sales at which sales milestone payments would be received						$ 2,500.0
Period for achieving sales target for milestone payment, rolling basis						12 months
Revenue, remaining performance obligation, variable consideration amount		$ 50.0	$ 50.0			$ 50.0
Sanofi Collaboration Agreement, Antibody | Minimum
Disaggregation of Revenue [Line Items]
Percentage of trial costs required to be funded by collaborating party						80.00%
Percentage share of profits to reimburse collaborating party						30.00%
Sanofi Collaboration Agreement, Antibody | Maximum
Disaggregation of Revenue [Line Items]
Percentage of trial costs required to be funded by collaborating party						100.00%
Percentage share of profits to reimburse collaborating party						50.00%